Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.11
-0.05 (-0.97%)
Sep 23, 2026, 10:15 AM EDT - Market open
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.67 billion as of September 23, 2026. Its market cap has increased by 112.67% in one year.
Market Cap
1.67B
Enterprise Value
1.27B
1-Year Change
112.67%
Ranking
Category
Stock Price
$5.11
ChartMarket Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.67B, an increase of 141.16%. That is a compound annual growth rate of 15.80%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 23, 2026 | 1.67B | 10.52% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Hemab Therapeutics Holdings | 1.79B |
| Novavax | 1.79B |
| Intellia Therapeutics | 1.78B |
| Tyra Biosciences | 1.76B |
| Nanobiotix | 1.76B |
| Immunocore Holdings | 1.67B |
| Kailera Therapeutics | 1.66B |
| Inhibrx Biosciences | 1.63B |